{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:42:54Z","timestamp":1792183374046,"version":"4.4.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Appl Genetics"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Gene therapies have recently emerged as promising strategies for treatment of previously incurable or poorly managed diseases. These hopes are particularly high in ophthalmology, as the eye is considered exceptionally suited for gene therapy. Expansion of gene therapy products may change the clinical course of treatment and give new chances to many patients. In this review, we address treatment possibilities and delivery methods as well as challenges and uncertainties related to gene therapy. We present inherited and acquired diseases which are subject to studies within this area, summarize current trends in ocular gene therapy, and indicate the future directions.<\/jats:p>","DOI":"10.1007\/s13353-025-00973-5","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T04:49:25Z","timestamp":1749098965000},"page":"325-337","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Gene therapy strategies in ophthalmology\u2014an overview of current developments and future prospects"],"prefix":"10.1007","volume":"67","author":[{"given":"Julia B.","family":"Krajewska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4950-6390","authenticated-orcid":false,"given":"Arleta","family":"Waszczykowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"973_CR1","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1124\/DMD.121.000418","volume":"50","author":"F Alhamadani","year":"2022","unstructured":"Alhamadani F, Zhang K, Parikh R et al (2022) Adverse drug reactions and toxicity of the Food and Drug Administration-approved antisense oligonucleotide drugs. Drug Metab Dispos 50:879\u2013887. https:\/\/doi.org\/10.1124\/DMD.121.000418","journal-title":"Drug Metab Dispos"},{"key":"973_CR2","doi-asserted-by":"publisher","unstructured":"Alvarez-Rivera F, Rey-Rico A, Venkatesan JK, et al (2020) Controlled release of rAAV vectors from APMA-functionalized contact lenses for corneal gene therapy. Pharmaceutics 12:. https:\/\/doi.org\/10.3390\/PHARMACEUTICS12040335","DOI":"10.3390\/PHARMACEUTICS12040335"},{"key":"973_CR3","doi-asserted-by":"publisher","first-page":"104","DOI":"10.2174\/1566523221666210423084233","volume":"22","author":"C Amador","year":"2022","unstructured":"Amador C, Shah R, Ghiam S et al (2022) Gene therapy in the anterior eye segment. Curr Gene Ther 22:104\u2013131. https:\/\/doi.org\/10.2174\/1566523221666210423084233","journal-title":"Curr Gene Ther"},{"key":"973_CR4","doi-asserted-by":"publisher","unstructured":"Ameri H, Kesavamoorthy N, Bruce DN (2023) Frequency and pattern of worldwide ocular gene therapy clinical trials up to 2022. Biomedicines 11:. https:\/\/doi.org\/10.3390\/BIOMEDICINES11123124","DOI":"10.3390\/BIOMEDICINES11123124"},{"key":"973_CR5","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/J.JCONREL.2024.01.063","volume":"367","author":"MB Appell","year":"2024","unstructured":"Appell MB, Pejavar J, Pasupathy A et al (2024) Next generation therapeutics for retinal neurodegenerative diseases. J Control Release 367:708\u2013736. https:\/\/doi.org\/10.1016\/J.JCONREL.2024.01.063","journal-title":"J Control Release"},{"key":"973_CR6","doi-asserted-by":"publisher","unstructured":"Arabi F, Mansouri V, Ahmadbeigi N (2022) Gene therapy clinical trials, where do we go? An overview. Biomed Pharmacother 153:. https:\/\/doi.org\/10.1016\/J.BIOPHA.2022.113324","DOI":"10.1016\/J.BIOPHA.2022.113324"},{"key":"973_CR7","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/J.JCONREL.2020.07.004","volume":"326","author":"P Baran-Rachwalska","year":"2020","unstructured":"Baran-Rachwalska P, Torabi-Pour N, Sutera FM et al (2020) Topical siRNA delivery to the cornea and anterior eye by hybrid silicon-lipid nanoparticles. J Control Release 326:192\u2013202. https:\/\/doi.org\/10.1016\/J.JCONREL.2020.07.004","journal-title":"J Control Release"},{"key":"973_CR8","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S0140-6736(16)30371-3","volume":"388","author":"J Bennett","year":"2016","unstructured":"Bennett J, Wellman J, Marshall KA et al (2016) Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. Lancet 388:661\u2013672. https:\/\/doi.org\/10.1016\/S0140-6736(16)30371-3","journal-title":"Lancet"},{"key":"973_CR9","doi-asserted-by":"publisher","unstructured":"Blasiak J, Pawlowska E, Ciupi\u0144ska J, et al (2024) A new generation of gene therapies as the future of wet AMD treatment. Int J Mol Sci 25:. https:\/\/doi.org\/10.3390\/IJMS25042386","DOI":"10.3390\/IJMS25042386"},{"key":"973_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/S40123-023-00862-2","volume":"13","author":"AS Brar","year":"2024","unstructured":"Brar AS, Parameswarappa DC, Takkar B et al (2024) Gene therapy for inherited retinal diseases: from laboratory bench to patient bedside and beyond. Ophthalmol Ther 13:21\u201350. https:\/\/doi.org\/10.1007\/S40123-023-00862-2","journal-title":"Ophthalmol Ther"},{"key":"973_CR11","doi-asserted-by":"publisher","unstructured":"Bucher K, Rodr\u00edguez-Bocanegra E, Dauletbekov D, Fischer MD (2021) Immune responses to retinal gene therapy using adeno-associated viral vectors - implications for treatment success and safety. Prog Retin Eye Res 83:. https:\/\/doi.org\/10.1016\/J.PRETEYERES.2020.100915","DOI":"10.1016\/J.PRETEYERES.2020.100915"},{"key":"973_CR12","doi-asserted-by":"publisher","first-page":"4534","DOI":"10.3390\/IJMS22094534","volume":"22","author":"W Chiu","year":"2021","unstructured":"Chiu W, Lin TY, Chang YC et al (2021) An update on gene therapy for inherited retinal dystrophy: experience in Leber congenital amaurosis clinical trials. Int J Mol Sci 22:4534. https:\/\/doi.org\/10.3390\/IJMS22094534","journal-title":"Int J Mol Sci"},{"key":"973_CR13","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1038\/S12276-023-01057-2","volume":"55","author":"EH Choi","year":"2023","unstructured":"Choi EH, Suh S, Sears AE et al (2023) Genome editing in the treatment of ocular diseases. Exp Mol Med 55:1678\u20131690. https:\/\/doi.org\/10.1038\/S12276-023-01057-2","journal-title":"Exp Mol Med"},{"key":"973_CR14","doi-asserted-by":"publisher","unstructured":"Clare AJ, Langer PM, Ward A, et al (2025) Characterization of the ocular inflammatory response to AAV reveals divergence by sex and age. Mol Ther 33:. https:\/\/doi.org\/10.1016\/J.YMTHE.2025.01.028","DOI":"10.1016\/J.YMTHE.2025.01.028"},{"key":"973_CR15","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/J.JTOS.2024.09.010","volume":"34","author":"L Cong","year":"2024","unstructured":"Cong L, Qi B, Ma W et al (2024) Preventing and treating neurotrophic keratopathy by a single intrastromal injection of AAV-mediated gene therapy. Ocul Surf 34:406\u2013414. https:\/\/doi.org\/10.1016\/J.JTOS.2024.09.010","journal-title":"Ocul Surf"},{"issue":"29","key":"973_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41434-020-00197-8","volume":"1","author":"MR Cring","year":"2020","unstructured":"Cring MR, Sheffield VC (2020) Gene therapy and gene correction: targets, progress, and challenges for treating human diseases. Gene Therapy 1(29):3\u201312. https:\/\/doi.org\/10.1038\/s41434-020-00197-8","journal-title":"Gene Therapy"},{"key":"973_CR17","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/J.DRUDIS.2019.01.019","volume":"24","author":"JJ Darrow","year":"2019","unstructured":"Darrow JJ (2019) Luxturna: FDA documents reveal the value of a costly gene therapy. Drug Discov Today 24:949\u2013954. https:\/\/doi.org\/10.1016\/J.DRUDIS.2019.01.019","journal-title":"Drug Discov Today"},{"key":"973_CR18","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/S00417-021-05508-2","volume":"260","author":"C Deng","year":"2022","unstructured":"Deng C, Zhao PY, Branham K et al (2022) Real-world outcomes of voretigene neparvovec treatment in pediatric patients with RPE65-associated Leber congenital amaurosis. Graefes Arch Clin Exp Ophthalmol 260:1543\u20131550. https:\/\/doi.org\/10.1007\/S00417-021-05508-2","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"973_CR19","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1089\/HUM.2019.026","volume":"30","author":"E Di Iorio","year":"2019","unstructured":"Di Iorio E, Barbaro V, Alvisi G et al (2019) New frontiers of corneal gene therapy. Hum Gene Ther 30:923\u2013945. https:\/\/doi.org\/10.1089\/HUM.2019.026","journal-title":"Hum Gene Ther"},{"key":"973_CR20","doi-asserted-by":"publisher","unstructured":"Doudna JA, Charpentier E (2014) Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 346:. https:\/\/doi.org\/10.1126\/SCIENCE.1258096","DOI":"10.1126\/SCIENCE.1258096"},{"key":"973_CR21","doi-asserted-by":"publisher","unstructured":"Fischer MD, Simonelli F, Sahni J, et al (2024) Real-world safety and effectiveness of voretigene neparvovec: results up to 2 years from the prospective, registry-based PERCEIVE study. Biomolecules 14:. https:\/\/doi.org\/10.3390\/BIOM14010122","DOI":"10.3390\/BIOM14010122"},{"key":"973_CR22","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1002\/CPT.3230","volume":"115","author":"JL Ford","year":"2024","unstructured":"Ford JL, Karatza E, Mody H et al (2024) Clinical pharmacology perspective on development of adeno-associated virus vector-based retina gene therapy. Clin Pharmacol Ther 115:1212\u20131232. https:\/\/doi.org\/10.1002\/CPT.3230","journal-title":"Clin Pharmacol Ther"},{"key":"973_CR23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/J.ORET.2021.03.016","volume":"6","author":"WS Gange","year":"2022","unstructured":"Gange WS, Sisk RA, Besirli CG et al (2022) Perifoveal chorioretinal atrophy after subretinal voretigene neparvovec-rzyl for RPE65-mediated Leber congenital amaurosis. Ophthalmol Retina 6:58\u201364. https:\/\/doi.org\/10.1016\/J.ORET.2021.03.016","journal-title":"Ophthalmol Retina"},{"key":"973_CR24","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/CEO.13917","volume":"49","author":"M Georgiou","year":"2021","unstructured":"Georgiou M, Fujinami K, Michaelides M (2021) Inherited retinal diseases: therapeutics, clinical trials and end points-a review. Clin Exp Ophthalmol 49:270\u2013288. https:\/\/doi.org\/10.1111\/CEO.13917","journal-title":"Clin Exp Ophthalmol"},{"key":"973_CR25","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.2147\/OPTH.S364200","volume":"16","author":"HH Ghoraba","year":"2022","unstructured":"Ghoraba HH, Akhavanrezayat A, Karaca I et al (2022) Ocular gene therapy: a literature review with special focus on immune and inflammatory responses. Clin Ophthalmol 16:1753\u20131771. https:\/\/doi.org\/10.2147\/OPTH.S364200","journal-title":"Clin Ophthalmol"},{"key":"973_CR26","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1016\/J.YMTHE.2024.09.007\/ATTACHMENT\/A69F129C-DAED-444B-AB4F-38957426F950\/MMC2.PDF","volume":"32","author":"BC Gilger","year":"2024","unstructured":"Gilger BC, Hasegawa T, Sutton RB et al (2024) A chimeric anti-inflammatory and anti-vascularization immunomodulator prevents high-risk corneal transplantation rejection via ex vivo gene therapy. Mol Ther 32:4006\u20134020. https:\/\/doi.org\/10.1016\/J.YMTHE.2024.09.007\/ATTACHMENT\/A69F129C-DAED-444B-AB4F-38957426F950\/MMC2.PDF","journal-title":"Mol Ther"},{"key":"973_CR27","first-page":"3023","volume":"57","author":"V Gonzalez","year":"2016","unstructured":"Gonzalez V, Moreno-Montanes J, Oll M et al (2016) Results of Phase IIB SYLTAG clinical trial with bamosiran in patients with glaucoma. Invest Ophthalmol vis Sci 57:3023\u20133023","journal-title":"Invest Ophthalmol vis Sci"},{"key":"973_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2019.00297\/BIBTEX","volume":"9","author":"R Goswami","year":"2019","unstructured":"Goswami R, Subramanian G, Silayeva L et al (2019) Gene therapy leaves a vicious cycle. Front Oncol 9:447742. https:\/\/doi.org\/10.3389\/FONC.2019.00297\/BIBTEX","journal-title":"Front Oncol"},{"key":"973_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0172928","volume":"12","author":"S Gupta","year":"2017","unstructured":"Gupta S, Rodier JT, Sharma A et al (2017) Targeted AAV5-Smad7 gene therapy inhibits corneal scarring in vivo. PLoS ONE 12:e0172928. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0172928","journal-title":"PLoS ONE"},{"issue":"5","key":"973_CR30","doi-asserted-by":"publisher","first-page":"1265293","DOI":"10.1080\/20016689.2017.1265293","volume":"1265293","author":"E Hanna","year":"2017","unstructured":"Hanna E, R\u00e9muzat C, Auquier P, Toumi M, (2017) Gene therapies development: slow progress and promising prospect. Journal of Market Access & Health Policy, (2017) Vol 5. Page 1265293(5):1265293. https:\/\/doi.org\/10.1080\/20016689.2017.1265293","journal-title":"Page"},{"key":"973_CR31","doi-asserted-by":"publisher","unstructured":"He X, Fu Y, Ma L, et al (2023) AAV for gene therapy in ocular diseases: progress and prospects. Research 6:. https:\/\/doi.org\/10.34133\/RESEARCH.0291","DOI":"10.34133\/RESEARCH.0291"},{"key":"973_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/J.OPHTHA.2024.06.013","author":"JS Heier","year":"2024","unstructured":"Heier JS, Cohen MN, Chao DL et al (2024) Phase 1 study of JNJ-81201887 gene therapy in geographic atrophy secondary to age-related macular degeneration. Ophthalmology. https:\/\/doi.org\/10.1016\/J.OPHTHA.2024.06.013","journal-title":"Ophthalmology"},{"key":"973_CR33","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1080\/08164622.2021.1880863","volume":"104","author":"ML Hu","year":"2021","unstructured":"Hu ML, Edwards TL, O\u2019Hare F et al (2021) Gene therapy for inherited retinal diseases: progress and possibilities. Clin Exp Optom 104:444\u2013454. https:\/\/doi.org\/10.1080\/08164622.2021.1880863","journal-title":"Clin Exp Optom"},{"key":"973_CR34","doi-asserted-by":"publisher","first-page":"11199","DOI":"10.1073\/PNAS.1706193114","volume":"114","author":"A Jain","year":"2017","unstructured":"Jain A, Zode G, Kasetti RB et al (2017) CRISPR-Cas9-based treatment of myocilin-associated glaucoma. Proc Natl Acad Sci U S A 114:11199\u201311204. https:\/\/doi.org\/10.1073\/PNAS.1706193114","journal-title":"Proc Natl Acad Sci U S A"},{"key":"973_CR35","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/S41433-022-02262-5","volume":"37","author":"A Jalil","year":"2022","unstructured":"Jalil A, Ivanova T, Moussa G et al (2022) Retinal gene therapy in RPE-65 gene mediated inherited retinal dystrophy. Eye 37:1874. https:\/\/doi.org\/10.1038\/S41433-022-02262-5","journal-title":"Eye"},{"key":"973_CR36","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/FCP.12561","volume":"35","author":"J Jiang","year":"2021","unstructured":"Jiang J, Zhang X, Tang Y et al (2021) Progress on ocular siRNA gene-silencing therapy and drug delivery systems. Fundam Clin Pharmacol 35:4\u201324. https:\/\/doi.org\/10.1111\/FCP.12561","journal-title":"Fundam Clin Pharmacol"},{"key":"973_CR37","doi-asserted-by":"publisher","unstructured":"Kiraly P, Cottriall CL, Taylor LJ, et al (2023) Outcomes and adverse effects of voretigene neparvovec treatment for biallelic RPE65-mediated inherited retinal dystrophies in a cohort of patients from a single center. Biomolecules 13:. https:\/\/doi.org\/10.3390\/BIOM13101484","DOI":"10.3390\/BIOM13101484"},{"key":"973_CR38","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/J.JCONREL.2007.05.041","volume":"124","author":"EA Klausner","year":"2007","unstructured":"Klausner EA, Peer D, Chapman RL et al (2007) Corneal gene therapy. J Control Release 124:107\u2013133. https:\/\/doi.org\/10.1016\/J.JCONREL.2007.05.041","journal-title":"J Control Release"},{"key":"973_CR39","doi-asserted-by":"publisher","unstructured":"Ku CA, Igelman AD, Huang SJ, et al (2024) Perimacular atrophy following voretigene neparvovec-rzyl treatment in the setting of previous contralateral eye treatment with a different viral vector. Transl Vis Sci Technol 13:. https:\/\/doi.org\/10.1167\/TVST.13.6.11","DOI":"10.1167\/TVST.13.6.11"},{"key":"973_CR40","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMRA0804630","volume":"360","author":"YH Kwon","year":"2009","unstructured":"Kwon YH, Fingert JH, Kuehn MH, Alward WLM (2009) Primary open-angle glaucoma. N Engl J Med 360:1113\u20131124. https:\/\/doi.org\/10.1056\/NEJMRA0804630","journal-title":"N Engl J Med"},{"key":"973_CR41","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/J.PRETEYERES.2018.08.003","volume":"68","author":"JH Lee","year":"2019","unstructured":"Lee JH, Wang JH, Chen J et al (2019) Gene therapy for visual loss: opportunities and concerns. Prog Retin Eye Res 68:31\u201353. https:\/\/doi.org\/10.1016\/J.PRETEYERES.2018.08.003","journal-title":"Prog Retin Eye Res"},{"key":"973_CR42","doi-asserted-by":"publisher","unstructured":"Liu LC, Chen YH, Lu DW (2023) Overview of recent advances in nano-based ocular drug delivery. Int J Mol Sci 24:. https:\/\/doi.org\/10.3390\/IJMS242015352","DOI":"10.3390\/IJMS242015352"},{"key":"973_CR43","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1515\/MEDGEN-2024-2067","volume":"37","author":"B Lorenz","year":"2025","unstructured":"Lorenz B (2025) Long-term experience with gene augmentation therapy in patients with inherited retinal disease associated with biallelic mutations in RPE65. Med Genet 37:47\u201356. https:\/\/doi.org\/10.1515\/MEDGEN-2024-2067","journal-title":"Med Genet"},{"issue":"15","key":"973_CR44","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3390\/V15030698","volume":"698","author":"K Lundstrom","year":"2023","unstructured":"Lundstrom K (2023) Viral vectors in gene therapy: where do we stand in 2023? Viruses 2023, Vol 15. Page 698(15):698. https:\/\/doi.org\/10.3390\/V15030698","journal-title":"Page"},{"key":"973_CR45","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/S41591-018-0327-9","volume":"25","author":"ML Maeder","year":"2019","unstructured":"Maeder ML, Stefanidakis M, Wilson CJ et al (2019) Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10. Nat Med 25:229\u2013233. https:\/\/doi.org\/10.1038\/S41591-018-0327-9","journal-title":"Nat Med"},{"key":"973_CR46","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/S0140-6736(09)61836-5","volume":"374","author":"AM Maguire","year":"2009","unstructured":"Maguire AM, High KA, Auricchio A et al (2009) Age-dependent effects of RPE65 gene therapy for Leber\u2019s congenital amaurosis: a phase 1 dose-escalation trial. Lancet 374:1597\u20131605. https:\/\/doi.org\/10.1016\/S0140-6736(09)61836-5","journal-title":"Lancet"},{"key":"973_CR47","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/J.OPHTHA.2019.06.017","volume":"126","author":"AM Maguire","year":"2019","unstructured":"Maguire AM, Russell S, Wellman JA et al (2019) Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation-associated inherited retinal dystrophy: results of phase 1 and 3 trials. Ophthalmology 126:1273\u20131285. https:\/\/doi.org\/10.1016\/J.OPHTHA.2019.06.017","journal-title":"Ophthalmology"},{"key":"973_CR48","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/S12950-025-00433-1","volume":"22","author":"DE Maidana","year":"2025","unstructured":"Maidana DE, Puente SP, Wang C et al (2025) Divergence in photoreceptor cell death and neuroinflammation in transvitreal and transscleral subretinal delivery in mice. J Inflamm (Lond) 22:5. https:\/\/doi.org\/10.1186\/S12950-025-00433-1","journal-title":"J Inflamm (Lond)"},{"key":"973_CR49","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.2147\/IDR.S315727","volume":"14","author":"MT Mascellino","year":"2021","unstructured":"Mascellino MT, Di Timoteo F, De Angelis M, Oliva A (2021) Overview of the main anti-SARS-CoV-2 vaccines: mechanism of action, efficacy and safety. Infect Drug Resist 14:3459\u20133476. https:\/\/doi.org\/10.2147\/IDR.S315727","journal-title":"Infect Drug Resist"},{"key":"973_CR50","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/J.ADDR.2004.12.007","volume":"57","author":"S Mehier-Humbert","year":"2005","unstructured":"Mehier-Humbert S, Guy RH (2005) Physical methods for gene transfer: improving the kinetics of gene delivery into cells. Adv Drug Deliv Rev 57:733\u2013753. https:\/\/doi.org\/10.1016\/J.ADDR.2004.12.007","journal-title":"Adv Drug Deliv Rev"},{"key":"973_CR51","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/J.ORET.2024.01.021","volume":"8","author":"P Melillo","year":"2024","unstructured":"Melillo P, Testa F, Di Iorio V et al (2024) Objective outcomes to evaluate voretigene neparvovec treatment effects in clinical practice. Ophthalmol Retina 8:688\u2013698. https:\/\/doi.org\/10.1016\/J.ORET.2024.01.021","journal-title":"Ophthalmol Retina"},{"key":"973_CR52","doi-asserted-by":"publisher","unstructured":"Mohan RR, Balne PK, Muayad MS, et al (2021) Six-month in vivo safety profiling of topical ocular AAV5-decorin gene transfer. Transl Vis Sci Technol 10:. https:\/\/doi.org\/10.1167\/TVST.10.10.5","DOI":"10.1167\/TVST.10.10.5"},{"key":"973_CR53","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/J.JTOS.2024.01.001","volume":"32","author":"RR Mohan","year":"2024","unstructured":"Mohan RR, Gupta S, Kumar R et al (2024) Tissue-targeted and localized AAV5-DCN and AAV5-PEDF combination gene therapy abrogates corneal fibrosis and concurrent neovascularization in rabbit eyes in vivo. Ocul Surf 32:13\u201325. https:\/\/doi.org\/10.1016\/J.JTOS.2024.01.001","journal-title":"Ocul Surf"},{"key":"973_CR54","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/MT.2013.217","volume":"22","author":"J Moreno-Monta\u00f1\u00e9s","year":"2014","unstructured":"Moreno-Monta\u00f1\u00e9s J, S\u00e1daba B, Ruz V et al (2014) Phase I clinical trial of SYL040012, a small interfering RNA targeting \u03b2-adrenergic receptor 2, for lowering intraocular pressure. Mol Ther 22:226\u2013232. https:\/\/doi.org\/10.1038\/MT.2013.217","journal-title":"Mol Ther"},{"key":"973_CR55","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/J.YMTHE.2022.03.004","volume":"30","author":"M Muhuri","year":"2022","unstructured":"Muhuri M, Levy DI, Schulz M et al (2022) Durability of transgene expression after rAAV gene therapy. Mol Ther 30:1364\u20131380. https:\/\/doi.org\/10.1016\/J.YMTHE.2022.03.004","journal-title":"Mol Ther"},{"key":"973_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13023-024-03099-9\/TABLES\/2","volume":"19","author":"QX Ng","year":"2024","unstructured":"Ng QX, Ong C, Yaow CYL et al (2024) Cost-of-illness studies of inherited retinal diseases: a systematic review. Orphanet J Rare Dis 19:1\u201311. https:\/\/doi.org\/10.1186\/S13023-024-03099-9\/TABLES\/2","journal-title":"Orphanet J Rare Dis"},{"key":"973_CR57","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1056\/NEJMOA2309915","volume":"390","author":"EA Pierce","year":"2024","unstructured":"Pierce EA, Aleman TS, Jayasundera KT et al (2024) Gene editing for CEP290-associated retinal degeneration. N Engl J Med 390:1972\u20131984. https:\/\/doi.org\/10.1056\/NEJMOA2309915","journal-title":"N Engl J Med"},{"key":"973_CR58","doi-asserted-by":"publisher","unstructured":"Purdy R, John M, Bray A, et al (2025) Gene therapy-associated uveitis (GTAU): understanding and mitigating the adverse immune response in retinal gene therapy. Prog Retin Eye Res 101354. https:\/\/doi.org\/10.1016\/J.PRETEYERES.2025.101354","DOI":"10.1016\/J.PRETEYERES.2025.101354"},{"key":"973_CR59","doi-asserted-by":"publisher","first-page":"8051","DOI":"10.1038\/S41598-025-92273-5","volume":"15","author":"P Rao","year":"2025","unstructured":"Rao P, Mishra M, Cashman SM et al (2025) AAV-IKV mediated expression of decorin inhibits EMT and fibrosis in a murine model of glaucoma and AAV-IKV transduction in non-human primates. Sci Rep 15:8051. https:\/\/doi.org\/10.1038\/S41598-025-92273-5","journal-title":"Sci Rep"},{"key":"973_CR60","doi-asserted-by":"publisher","unstructured":"Rodrigues GA, Shalaev E, Karami TK, et al (2018) Pharmaceutical development of AAV-based gene therapy products for the eye. Pharm Res 36:. https:\/\/doi.org\/10.1007\/S11095-018-2554-7","DOI":"10.1007\/S11095-018-2554-7"},{"key":"973_CR61","doi-asserted-by":"publisher","unstructured":"Rowe LW, Ciulla TA (2024) Gene therapy for non-hereditary retinal disease: age-related macular degeneration, diabetic retinopathy, and beyond. Genes (Basel) 15:. https:\/\/doi.org\/10.3390\/GENES15060720","DOI":"10.3390\/GENES15060720"},{"key":"973_CR62","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","volume":"390","author":"S Russell","year":"2017","unstructured":"Russell S, Bennett J, Wellman JA et al (2017) Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. The Lancet 390:849\u2013860. https:\/\/doi.org\/10.1016\/S0140-6736(17)31868-8","journal-title":"The Lancet"},{"key":"973_CR63","doi-asserted-by":"publisher","unstructured":"Sahu B, Chug I, Khanna H (2021) The ocular gene delivery landscape. Biomolecules 11:. https:\/\/doi.org\/10.3390\/BIOM11081135","DOI":"10.3390\/BIOM11081135"},{"key":"973_CR64","doi-asserted-by":"publisher","unstructured":"Sainz\u2010Ramos M, Gallego I, Villate\u2010Beitia I, et al (2021) How far are non-viral vectors to come of age and reach clinical translation in gene therapy? Int J Mol Sci 22:. https:\/\/doi.org\/10.3390\/IJMS22147545","DOI":"10.3390\/IJMS22147545"},{"key":"973_CR65","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1016\/J.CLINTHERA.2021.08.011","volume":"43","author":"NM Schultz","year":"2021","unstructured":"Schultz NM, Bhardwaj S, Barclay C et al (2021) Global burden of dry age-related macular degeneration: a targeted literature review. Clin Ther 43:1792\u20131818. https:\/\/doi.org\/10.1016\/J.CLINTHERA.2021.08.011","journal-title":"Clin Ther"},{"key":"973_CR66","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/J.ORET.2021.11.005","volume":"6","author":"JD Sengillo","year":"2022","unstructured":"Sengillo JD, Gregori NZ, Sisk RA et al (2022) Visual acuity, retinal morphology, and patients\u2019 perceptions after voretigene neparovec-rzyl therapy for RPE65-associated retinal disease. Ophthalmol Retina 6:273\u2013283. https:\/\/doi.org\/10.1016\/J.ORET.2021.11.005","journal-title":"Ophthalmol Retina"},{"key":"973_CR67","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/J.EJPB.2014.12.022","volume":"95","author":"M\u00c1 Solin\u00eds","year":"2015","unstructured":"Solin\u00eds M\u00c1, Del Pozo-Rodr\u00edguez A, Apaolaza PS, Rodr\u00edguez-Gasc\u00f3n A (2015) Treatment of ocular disorders by gene therapy. Eur J Pharm Biopharm 95:331\u2013342. https:\/\/doi.org\/10.1016\/J.EJPB.2014.12.022","journal-title":"Eur J Pharm Biopharm"},{"key":"973_CR68","doi-asserted-by":"publisher","unstructured":"Stingl K, Kempf M, Jung R, Stingl K (2024) Chorioretinal atrophy growth after voretigene neparvovec retinotopically is connected to retinal functional rescue. Transl Vis Sci Technol 13:. https:\/\/doi.org\/10.1167\/TVST.13.2.13","DOI":"10.1167\/TVST.13.2.13"},{"key":"973_CR69","doi-asserted-by":"publisher","first-page":"92","DOI":"10.4103\/1673-5374.375319","volume":"19","author":"R Sulak","year":"2024","unstructured":"Sulak R, Liu X, Smedowski A (2024) The concept of gene therapy for glaucoma: the dream that has not come true yet. Neural Regen Res 19:92\u201399. https:\/\/doi.org\/10.4103\/1673-5374.375319","journal-title":"Neural Regen Res"},{"key":"973_CR70","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1073\/PNAS.48.12.2026\/ASSET\/7BE5DBF7-1B4C-429E-8D7F-617A425721BA\/ASSETS\/PNAS.48.12.2026.FP.PNG","volume":"48","author":"EH Szybalska","year":"1962","unstructured":"Szybalska EH, Szybalski W (1962) Genetics of human cess line. IV. DNA-mediated heritable transformation of a biochemical trait. Proc Natl Acad Sci U S A 48:2026\u20132034. https:\/\/doi.org\/10.1073\/PNAS.48.12.2026\/ASSET\/7BE5DBF7-1B4C-429E-8D7F-617A425721BA\/ASSETS\/PNAS.48.12.2026.FP.PNG","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"973_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-16308-2","volume":"1","author":"Y Taketani","year":"2017","unstructured":"Taketani Y, Kitamoto K, Sakisaka T et al (2017) Repair of the TGFBI gene in human corneal keratocytes derived from a granular corneal dystrophy patient via CRISPR\/Cas9-induced homology-directed repair. Scientific Reports 1(7):1\u20137. https:\/\/doi.org\/10.1038\/s41598-017-16308-2","journal-title":"Scientific Reports"},{"key":"973_CR72","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/S11010-020-03834-3","volume":"474","author":"R Tang","year":"2020","unstructured":"Tang R, Xu Z (2020) Gene therapy: a double-edged sword with great powers. Mol Cell Biochem 474:73\u201381. https:\/\/doi.org\/10.1007\/S11010-020-03834-3","journal-title":"Mol Cell Biochem"},{"key":"973_CR73","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1002\/JLB.3MIR0817-337R","volume":"103","author":"AW Taylor","year":"2018","unstructured":"Taylor AW, Ng TF (2018) Negative regulators that mediate ocular immune privilege. J Leukoc Biol 103:1179\u20131187. https:\/\/doi.org\/10.1002\/JLB.3MIR0817-337R","journal-title":"J Leukoc Biol"},{"key":"973_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/S41433-024-03065-6","author":"F Testa","year":"2024","unstructured":"Testa F, Bacci G, Falsini B et al (2024) Voretigene neparvovec for inherited retinal dystrophy due to RPE65 mutations: a scoping review of eligibility and treatment challenges from clinical trials to real practice. Eye (Lond). https:\/\/doi.org\/10.1038\/S41433-024-03065-6","journal-title":"Eye (Lond)"},{"key":"973_CR75","doi-asserted-by":"publisher","unstructured":"Testa F, Melillo P, Di Iorio V, et al (2022) Visual function and retinal changes after voretigene neparvovec treatment in children with biallelic RPE65-related inherited retinal dystrophy. Sci Rep 12:. https:\/\/doi.org\/10.1038\/S41598-022-22180-6","DOI":"10.1038\/S41598-022-22180-6"},{"key":"973_CR76","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/J.JCONREL.2018.07.013","volume":"285","author":"E Touchard","year":"2018","unstructured":"Touchard E, Benard R, Bigot K et al (2018) Non-viral ocular gene therapy, pEYS606, for the treatment of non-infectious uveitis: preclinical evaluation of the medicinal product. J Control Release 285:244\u2013251. https:\/\/doi.org\/10.1016\/J.JCONREL.2018.07.013","journal-title":"J Control Release"},{"key":"973_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/J.SURVOPHTHAL.2024.05.002","author":"J Trinc\u00e3o-Marques","year":"2024","unstructured":"Trinc\u00e3o-Marques J, Ayton LN, Hickey DG et al (2024) Gene and cell therapy for age-related macular degeneration: a review. Surv Ophthalmol. https:\/\/doi.org\/10.1016\/J.SURVOPHTHAL.2024.05.002","journal-title":"Surv Ophthalmol"},{"key":"973_CR78","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1167\/IOVS.62.2.41","volume":"62","author":"G Tummala","year":"2021","unstructured":"Tummala G, Crain A, Rowlan J, Pepple KL (2021) Characterization of gene therapy associated uveitis following intravitreal adeno-associated virus injection in mice. Invest Ophthalmol vis Sci 62:41. https:\/\/doi.org\/10.1167\/IOVS.62.2.41","journal-title":"Invest Ophthalmol vis Sci"},{"key":"973_CR79","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/J.YMTHE.2019.12.010","volume":"28","author":"HC Verdera","year":"2020","unstructured":"Verdera HC, Kuranda K, Mingozzi F (2020) AAV vector immunogenicity in humans: a long journey to successful gene transfer. Mol Ther 28:723\u2013746. https:\/\/doi.org\/10.1016\/J.YMTHE.2019.12.010","journal-title":"Mol Ther"},{"key":"973_CR80","doi-asserted-by":"publisher","unstructured":"Wang T, Yu T, Liu Q, et al (2024) Lipid nanoparticle technology-mediated therapeutic gene manipulation in the eyes. Mol Ther Nucleic Acids 35:. https:\/\/doi.org\/10.1016\/J.OMTN.2024.102236","DOI":"10.1016\/J.OMTN.2024.102236"},{"key":"973_CR81","doi-asserted-by":"publisher","unstructured":"Wasnik VB, Thool AR (2022) Ocular gene therapy: a literature review with focus on current clinical trials. Cureus 14:. https:\/\/doi.org\/10.7759\/CUREUS.29533","DOI":"10.7759\/CUREUS.29533"},{"key":"973_CR82","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1016\/J.YMTHE.2023.08.021","volume":"31","author":"A Wei","year":"2023","unstructured":"Wei A, Yin D, Zhai Z et al (2023) In vivo CRISPR gene editing in patients with herpetic stromal keratitis. Mol Ther 31:3163\u20133175. https:\/\/doi.org\/10.1016\/J.YMTHE.2023.08.021","journal-title":"Mol Ther"},{"key":"973_CR83","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/S41587-020-00781-8","volume":"39","author":"D Yin","year":"2021","unstructured":"Yin D, Ling S, Wang D et al (2021) Targeting herpes simplex virus with CRISPR-Cas9 cures herpetic stromal keratitis in mice. Nat Biotechnol 39:567\u2013577. https:\/\/doi.org\/10.1038\/S41587-020-00781-8","journal-title":"Nat Biotechnol"},{"key":"973_CR84","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/J.OMTM.2020.01.002","volume":"16","author":"G Yiu","year":"2020","unstructured":"Yiu G, Chung SH, Mollhoff IN et al (2020) Suprachoroidal and subretinal injections of AAV using transscleral microneedles for retinal gene delivery in nonhuman primates. Mol Ther Methods Clin Dev 16:179\u2013191. https:\/\/doi.org\/10.1016\/J.OMTM.2020.01.002","journal-title":"Mol Ther Methods Clin Dev"},{"key":"973_CR85","doi-asserted-by":"publisher","unstructured":"Yu AM, Tu MJ (2022) Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination. Pharmacol Ther 230:. https:\/\/doi.org\/10.1016\/J.PHARMTHERA.2021.107967","DOI":"10.1016\/J.PHARMTHERA.2021.107967"},{"key":"973_CR86","doi-asserted-by":"publisher","unstructured":"(2020) First CRISPR therapy dosed. Nat Biotechnol 38:382. https:\/\/doi.org\/10.1038\/S41587-020-0493-4","DOI":"10.1038\/S41587-020-0493-4"}],"container-title":["Journal of Applied Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13353-025-00973-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13353-025-00973-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13353-025-00973-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T02:43:22Z","timestamp":1776221002000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13353-025-00973-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["973"],"URL":"https:\/\/doi.org\/10.1007\/s13353-025-00973-5","relation":{},"ISSN":["1234-1983","2190-3883"],"issn-type":[{"value":"1234-1983","type":"print"},{"value":"2190-3883","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]},"assertion":[{"value":"14 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}}]}}